While in the clinical trial experience with Xyrem in narcolepsy/cataplexy clients at therapeutic doses, two individuals documented anxiousness and one described sleeplessness subsequent abrupt discontinuation for the termination from the medical demo; in The 2 people with panic, the frequency of cataplexy experienced elevated markedly simultaneousl